About Kevin Ryan
Form D filings for Affect Therapeutics from 2021 to 2023 list Kevin Ryan as director.
Kevin Ryan first appears on SEC filings in 2021.
Experience
This experience comes from SEC filings. The years are when the filings name Kevin Ryan in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Kevin Ryan works with at each company, as listed on that company's latest Form D.
Affect Therapeutics, Inc. · Form D, Jul 12, 2023
JR
Jeff Rinehart
Director
JD
Jeff DeFlavio
Director
SP
Stuart Peterson
Director
KM
Kristin Muhlner
Chief Executive Officer and director